Cash Cash Equivalents - InterCure Ltd (NASDAQ:INCR) - Alpha Spread
I

InterCure Ltd
NASDAQ:INCR

Watchlist Manager
InterCure Ltd
NASDAQ:INCR
Watchlist
Price: 1.86 USD Market Closed
Market Cap: 84.8m USD
Have any thoughts about
InterCure Ltd?
Write Note

InterCure Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

InterCure Ltd
Cash & Cash Equivalents Peer Comparison

Comparables:
TEVA
RDHL
SLGL
MDWD
R
REKA

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
I
InterCure Ltd
NASDAQ:INCR
Cash & Cash Equivalents
â‚Ş101.1m
CAGR 3-Years
39%
CAGR 5-Years
97%
CAGR 10-Years
63%
Teva Pharmaceutical Industries Ltd
NYSE:TEVA
Cash & Cash Equivalents
$2.3B
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
9%
Redhill Biopharma Ltd
NASDAQ:RDHL
Cash & Cash Equivalents
$7.3m
CAGR 3-Years
-48%
CAGR 5-Years
-4%
CAGR 10-Years
-8%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Cash & Cash Equivalents
$11.5m
CAGR 3-Years
1%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Mediwound Ltd
NASDAQ:MDWD
Cash & Cash Equivalents
$3.8m
CAGR 3-Years
-40%
CAGR 5-Years
-31%
CAGR 10-Years
-16%
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Cash & Cash Equivalents
â‚Ş11m
CAGR 3-Years
-34%
CAGR 5-Years
-30%
CAGR 10-Years
-11%

See Also

What is InterCure Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
101.1m ILS

Based on the financial report for Dec 31, 2023, InterCure Ltd's Cash & Cash Equivalents amounts to 101.1m ILS.

What is InterCure Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
63%

Over the last year, the Cash & Cash Equivalents growth was -57%. The average annual Cash & Cash Equivalents growth rates for InterCure Ltd have been 39% over the past three years , 97% over the past five years , and 63% over the past ten years .

Back to Top